The clinical implications of the genetics of renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 2, 2009, Pages 131-136

  Rosner, Inger ^a   Bratslavsky, Gennady ^a   Pinto, Peter A ^a   Linehan, W Marston ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BHD; Gene; HLRCC; HPRC; Renal cell carcinoma; VHL

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; FUMARATE HYDRATASE; INTERLEUKIN 2; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; VON HIPPEL LINDAU PROTEIN;

BHD GENE; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CHINESE MEDICINE; CHROMOSOME 3; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; FAMILIAL DISEASE; GENE MUTATION; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LAPAROSCOPIC SURGERY; MOLECULAR GENETICS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; REVIEW; RNA TRANSLATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GENE; VON HIPPEL LINDAU DISEASE;

CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; LEIOMYOMATOSIS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; VON HIPPEL-LINDAU DISEASE;

EID: 61649115441     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.11.001     Document Type: Review

References (54)

1. SEER Cancer Statistics Review, 1975-2005. NCI 2007; (November 2007 SEER data submission. Available from URL: http://seer.cancer.gov/csr/1975_2005/results_merged/sect_01_overview.pdf and http://seer.cancer.gov/csr/1975_2005/results_merged/sect_11_kidney_pelvis.pdf).
2. Chow W.H., Devesa S.S., Warren J.L., et al. Rising incidence of renal cell cancer in the United States. J Am Med Assoc 281 (1999) 1628-1631
3. Uchida K., Miyao N., Masumori N., et al. Recurrence of renal cell carcinoma more than 5 years after nephrectomy. Int J Urol 9 (2002) 19-23
4. Linehan W.M., Walther M.M., and Zbar B. The genetic basis of cancer of the kidney. J Urol 170 (2003) 2163-2172
5. Linehan W.M., Vasselli J., Srinivasan R., et al. Genetic basis of cancer of the kidney: Disease-specific approaches to therapy. Clin Cancer Res 10 (2004) 6282S-6289S
6. Kovacs G., Emanuel A., Neumann H.P., et al. Cytogenetics of renal cell carcinomas associated with von Hippel-Lindau disease. Genes Chromosomes Cancer 3 (1991) 256-262
7. Zbar B., Brauch H., Talmadge C., et al. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327 (1987) 721-724
8. Knudson A.G. Genetics of human cancer. Annu Rev Genet 20 (1986) 231-251
9. Walther M.M., Lubensky I.A., Venzon D., et al. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma, and no renal disease: Clinical implications. J Urol 154 (1995) 2010-2014
10. Tory K., Brauch H., Linehan W.M., et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 81 (1989) 1097-1101
11. Latif F., Tory K., Gnarra J.R., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
12. Stolle C., Glenn G.M., Zbar B., et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12 (1998) 417-423
13. Chen F., Kishida T., Yao M., et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5 (1995) 66-75
14. Ong K.R., Woodward E.R., Killick P., et al. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 28 (2007) 143-149
15. Neumann H.P.H., and Zbar B. Renal cysts, renal cancer, and von Hippel-Lindau disease. Kidney Int 51 (1997) 16-26
16. Maranchie J.K., Afonso A., Albert P.S., et al. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat 23 (2004) 40-46
17. Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Gen 7 (1994) 85-90
18. Shuin T., Kondo K., Torigoe S., et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54 (1994) 2852-2855
19. Duan D.R., Pause A., Burgess W.H., et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269 (1995) 1402-1406
20. Kibel A., Iliopoulos O., DeCaprio J.A., et al. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269 (1995) 1444-1446
21. Pause A, Lee S, Worrell RA, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 91997;4:2156-61.
22. Iliopoulos O., Jiang C., Levy A.P., et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93 (1996) 10595-10599
23. Brugarolas J., and Kaelin Jr. W.G. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6 (2004) 7-10
24. Linehan W.M. Editorial: Kidney Cancer, A Unique Opportunity for the Development of Disease Specific Therapy. J Urol 168 (2002) 2411-2412
25. Zbar B., Tory K., Merino M.J., et al. Hereditary papillary renal cell carcinoma. J Urol 151 (1994) 561-566
26. Schmidt L., Duh F.M., Chen F., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Gen 16 (1997) 68-73
27. Schmidt L., Junker K., Weirich G., et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58 (1998) 1719-1722
28. Schmidt L.S., Nickerson M.L., Angeloni D., et al. Early onset hereditary papillary renal carcinoma: Germline missense mutations in the tyrosine kinase domain of the Met proto-oncogene. J Urol 172 Part 1 (2004) 1256-1261
29. Choyke P.L., Walther M.M., Glenn G.M., et al. Imaging features of hereditary papillary renal cancers. J Comput Assist Tomogr 21 (1997) 737-741
30. Bottaro D.P., Rubin J.S., Faletto D.L., et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251 (1991) 802-804
31. Zhang Y.W., and Vande Woude G.F. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88 (2003) 408-417
32. Kovacs G. Molecular cytogenetics of renal cell tumors. Adv Cancer Res 62 (1993) 89-124
33. Zhuang Z., Park W.S., Pack S., et al. Trisomy 7-harboring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 20 (1998) 66-69
34. Zbar B., Alvord W.G., Glenn G.M., et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 11 (2002) 393-400
35. Pavlovich C.P., Walther M.M., Eyler R.A., et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 26 (2002) 1542-1552
36. Schmidt L.S., Warren M.B., Nickerson M.L., et al. Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 69 (2001) 876-882
37. Nickerson M.L., Warren M.B., Toro J.R., et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 4 (2002) 157-164
38. Schmidt L.S., Nickerson M.L., Warren M.B., et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 76 (2005) 1023-1033
39. Vocke C.D., Yang Y., Pavlovich C.P., et al. High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-Hogg-Dube-Associated Renal Tumors. J Natl Cancer Inst 97 (2005) 931-935
40. Launonen V., Vierimaa O., Kiuru M., et al. Inherited Susceptibility to uterine leiomyomas and renal cell cancer. Proc Nat. Acad Sci USA 98 (2002) 3387-3392
41. Merino M.J., Torres-Cabala C., Pinto P., et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31 (2007) 1578-1585
42. Tomlinson I.P., Alam N.A., Rowan A.J., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata, and papillary renal cell cancer. Nat Gen 30 (2002) 406-410
43. Isaacs J.S., Jung Y.J., Mole D.R., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell 8 (2005) 143-153
44. Toro J.R., Nickerson M.L., Wei M.H., et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 73 (2003) 95-106
45. Walther M.M., Choyke P.L., Glenn G.M., et al. Renal cancer in families with hereditary renal cancer: Prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 161 (1999) 1475-1479
46. Duffey B.G., Choyke P.L., Glenn G.M., et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau Disease. J Urol 172 (2004) 63-65
47. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
48. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
49. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
50. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon-α in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
51. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
52. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
53. Sudarshan S., Linehan W.M., and Neckers L. HIF and fumarate hydratase in renal cancer. Br J Cancer 96 (2007) 403-407
54. Linehan W.M., and Zbar B. Focus on kidney cancer. Cancer Cell 6 (2004) 223-228